Avacta Group Plc (AVCTF)
USD 0.59
(0.0%)
USD 0.59
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 73.19 Million GBP | -21.0% |
| 2022 | 92.64 Million GBP | 97.12% |
| 2021 | 47 Million GBP | -30.33% |
| 2020 | 67.46 Million GBP | 137.46% |
| 2019 | 28.41 Million GBP | 21.14% |
| 2018 | 23.45 Million GBP | -25.67% |
| 2017 | 31.55 Million GBP | -15.98% |
| 2016 | 37.55 Million GBP | 75.46% |
| 2015 | 21.4 Million GBP | -31.07% |
| 2014 | 31.04 Million GBP | 75.87% |
| 2013 | 17.65 Million GBP | -4.51% |
| 2012 | 18.48 Million GBP | 49.88% |
| 2011 | 12.33 Million GBP | 9.92% |
| 2010 | 11.22 Million GBP | 23.93% |
| 2009 | 9.05 Million GBP | 76.03% |
| 2008 | 5.14 Million GBP | 80.81% |
| 2007 | 2.84 Million GBP | 8521.21% |
| 2006 | 33 Thousand GBP | -84.65% |
| 2005 | 215 Thousand GBP | -84.44% |
| 2004 | 1.38 Million GBP | 659.34% |
| 2003 | 182 Thousand GBP | 1.68% |
| 2002 | 179 Thousand GBP | -15.57% |
| 2001 | 212 Thousand GBP | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q2 | 87.74 Million GBP | 0.0% |
| 2023 Q3 | 73.19 Million GBP | -16.59% |
| 2023 FY | 73.19 Million GBP | -21.0% |
| 2023 Q4 | 73.19 Million GBP | 0.0% |
| 2023 Q1 | 87.74 Million GBP | -5.29% |
| 2022 Q4 | 92.64 Million GBP | 0.0% |
| 2022 FY | 92.64 Million GBP | 97.12% |
| 2022 Q1 | 45.46 Million GBP | -3.28% |
| 2022 Q2 | 45.46 Million GBP | 0.0% |
| 2022 Q3 | 92.64 Million GBP | 103.8% |
| 2021 Q3 | 47 Million GBP | -22.06% |
| 2021 Q4 | 47 Million GBP | 0.0% |
| 2021 FY | 47 Million GBP | -30.33% |
| 2021 Q1 | 60.3 Million GBP | -10.6% |
| 2021 Q2 | 60.3 Million GBP | 0.0% |
| 2020 Q3 | 67.46 Million GBP | -10.2% |
| 2020 Q1 | 75.12 Million GBP | 0.0% |
| 2020 Q2 | 75.12 Million GBP | 0.0% |
| 2020 Q4 | 67.46 Million GBP | 0.0% |
| 2020 FY | 67.46 Million GBP | 137.46% |
| 2019 FY | 28.41 Million GBP | 21.14% |
| 2019 Q1 | 25.72 Million GBP | -17.33% |
| 2019 Q2 | 25.72 Million GBP | 0.0% |
| 2018 Q4 | 31.11 Million GBP | 0.0% |
| 2018 FY | 23.45 Million GBP | -25.67% |
| 2018 Q2 | 23.45 Million GBP | 0.0% |
| 2018 Q1 | 23.45 Million GBP | -16.12% |
| 2017 Q1 | 31.55 Million GBP | -7.77% |
| 2017 FY | 31.55 Million GBP | -15.98% |
| 2017 Q4 | 27.96 Million GBP | 0.0% |
| 2017 Q3 | 27.96 Million GBP | -11.39% |
| 2017 Q2 | 31.55 Million GBP | 0.0% |
| 2016 Q1 | 37.55 Million GBP | -6.59% |
| 2016 FY | 37.55 Million GBP | 75.46% |
| 2016 Q3 | 34.21 Million GBP | -8.89% |
| 2016 Q4 | 34.21 Million GBP | 0.0% |
| 2016 Q2 | 37.55 Million GBP | 0.0% |
| 2015 FY | 21.4 Million GBP | -31.07% |
| 2015 Q3 | 40.2 Million GBP | 87.84% |
| 2015 Q1 | 21.4 Million GBP | -11.51% |
| 2015 Q2 | 21.4 Million GBP | 0.0% |
| 2015 Q4 | 40.2 Million GBP | 0.0% |
| 2014 Q3 | 24.18 Million GBP | -22.1% |
| 2014 FY | 31.04 Million GBP | 75.87% |
| 2014 Q1 | 31.04 Million GBP | 44.8% |
| 2014 Q2 | 31.04 Million GBP | 0.0% |
| 2014 Q4 | 24.18 Million GBP | 0.0% |
| 2013 Q4 | 21.44 Million GBP | 0.0% |
| 2013 Q1 | 17.65 Million GBP | 1.92% |
| 2013 Q2 | 17.65 Million GBP | 0.0% |
| 2013 FY | 17.65 Million GBP | -4.51% |
| 2013 Q3 | 21.44 Million GBP | 21.46% |
| 2012 Q4 | 17.32 Million GBP | 0.0% |
| 2012 Q2 | 18.48 Million GBP | 0.0% |
| 2012 Q3 | 17.32 Million GBP | -6.3% |
| 2012 FY | 18.48 Million GBP | 49.88% |
| 2011 FY | 12.33 Million GBP | 9.92% |
| 2011 Q4 | 18.57 Million GBP | 0.0% |
| 2011 Q2 | 12.33 Million GBP | 0.0% |
| 2010 Q4 | 12.54 Million GBP | 0.0% |
| 2010 Q2 | 11.22 Million GBP | 0.0% |
| 2010 FY | 11.22 Million GBP | 23.93% |
| 2009 Q4 | 9.96 Million GBP | 0.0% |
| 2009 Q2 | 9.05 Million GBP | 0.0% |
| 2009 FY | 9.05 Million GBP | 76.03% |
| 2008 FY | 5.14 Million GBP | 80.81% |
| 2008 Q4 | 5.94 Million GBP | 0.0% |
| 2008 Q2 | 5.14 Million GBP | 0.0% |
| 2007 Q4 | 6.05 Million GBP | 0.0% |
| 2007 FY | 2.84 Million GBP | 8521.21% |
| 2006 FY | 33 Thousand GBP | -84.65% |
| 2006 Q1 | 33 Thousand GBP | 0.0% |
| 2006 Q3 | - GBP | 0.0% |
| 2005 FY | 215 Thousand GBP | -84.44% |
| 2005 Q3 | 404 Thousand GBP | 0.0% |
| 2005 Q1 | 215 Thousand GBP | 0.0% |
| 2004 FY | 1.38 Million GBP | 659.34% |
| 2004 Q1 | 1.38 Million GBP | 0.0% |
| 2004 Q3 | 1.24 Million GBP | 0.0% |
| 2003 FY | 182 Thousand GBP | 1.68% |
| 2003 Q3 | 1.59 Million GBP | 0.0% |
| 2002 FY | 179 Thousand GBP | -15.57% |
| 2001 FY | 212 Thousand GBP | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -88.408% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -913.759% |
| SQZ Biotechnologies Company | 107.18 Million USD | 31.717% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -593.491% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 43.79% |
| Mesoblast Limited | 667.9 Million USD | 89.042% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -101041.436% |
| Genus plc | 1.02 Billion USD | 92.886% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -5288.216% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -14566.389% |
| Marizyme, Inc. | 22.01 Million USD | -232.459% |
| ContraFect Corporation | 20.67 Million USD | -253.939% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -11573.206% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -18649.328% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -19051.074% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -5010.989% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -1665.331% |
| MultiCell Technologies, Inc. | 126.22 USD | -57986748.36% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -7688.854% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 43.046% |
| EV Biologics, Inc. | 431.71 Thousand USD | -16853.585% |
| Q BioMed Inc. | 3.51 Million USD | -1981.941% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -108.053% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -9397.381% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -27912.799% |
| Biomind Labs Inc. | 73.81 Thousand USD | -99049.271% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 84.187% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -143.848% |
| Skye Bioscience, Inc. | 11.94 Million USD | -512.969% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -2109.198% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -2565.043% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -3637.688% |
| IMV Inc. | 31.33 Million USD | -133.585% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -10546.18% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -2711.582% |
| GB Sciences, Inc. | 103.44 Thousand USD | -70655.593% |
| Alpha Cognition Inc. | 2.45 Million USD | -2884.744% |
| HST Global, Inc. | 1526.00 USD | -4796164.744% |
| CSL Limited | 38.02 Billion USD | 99.808% |
| Halberd Corporation | 10.13 Thousand USD | -722345.958% |
| Enzolytics Inc. | 361.7 Million USD | 79.765% |
| Resverlogix Corp. | 8.11 Million USD | -801.922% |
| Affymax, Inc. | 7.44 Million USD | -883.353% |
| SYBLEU INC | 330.46 Thousand USD | -22047.681% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -3797.533% |
| argenx SE | 4.54 Billion USD | 98.389% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -161.92% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -53.434% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -321180.892% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -717.854% |
| AVAX Technologies, Inc. | 7.37 Million USD | -892.13% |
| Zenith Capital Corp. | 7410.00 USD | -987632.794% |
| Genscript Biotech Corporation | 3.38 Billion USD | 97.839% |
| Ember Therapeutics, Inc. | 184.00 USD | -39777617.391% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -22643.827% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -27903.474% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 83.601% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -4951.686% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | -2319.468% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -38.88% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -7787.293% |
| BioStem Technologies, Inc. | 14.56 Million USD | -402.675% |
| ONE Bio Corp. | 70.08 Million USD | -4.431% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -128093.856% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -3168341.558% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -7308.243% |
| Agentix Corp. | 261.39 Thousand USD | -27900.474% |
| LadRx Corporation | 2.3 Million USD | -3071.349% |
| Cell Source, Inc. | 195.17 Thousand USD | -37400.961% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -15130.451% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -20597.817% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -20597.817% |
| NovAccess Global Inc. | 62.24 Thousand USD | -117479.681% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -11342.244% |
| Itoco Inc. | 1.4 Million USD | -5127.66% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -76414.003% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -68948.113% |
| Kadimastem Ltd | 2.3 Million USD | -3076.582% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -95757.453% |
| CytoDyn Inc. | 11.13 Million USD | -557.247% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -51092.541% |
| Mobile Lads Corp. | 52.00 USD | -140751823.077% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -409245.638% |
| Qrons Inc. | 420.00 USD | -17426328.571% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -18887.421% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -13156.357% |
| Rebus Holdings, Inc. | 5000.00 USD | -1463720.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -17776.665% |
| International Stem Cell Corporation | 5.39 Million USD | -1257.904% |
| Bioxytran, Inc. | 137.63 Thousand USD | -53076.448% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -387.88% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -341.468% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -92546.835% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -8364.548% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -873.673% |
| Neutra Corp. | 2851.00 USD | -2567104.49% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -125.856% |
| PureTech Health plc | 693.97 Million USD | 89.453% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -806.829% |
| IXICO plc | 15.84 Million USD | -361.951% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -783.736% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 29.164% |
| CSL Limited | 38.02 Billion USD | 99.808% |
| Cellectis S.A. | 333.99 Million USD | 78.086% |